Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages E4485-E4494

  Tucker, Kristal R ^a   Block, Ethan R ^a   Levitan, Edwin S ^a   Edwards, Robert H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Antiporter; Multiphoton; Vesicular release; VMAT

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATASE; AMPHETAMINE; BAFILOMYCIN A1; CYAMEMAZINE; DOPAMINE TRANSPORTER; FLUOXETINE; MONOAMINE; NOMIFENSINE; RESERPINE; VANOXERINE; VESICULAR MONOAMINE TRANSPORTER; ACID; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPHOTON MICROSCOPY; NERVE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPSE VESICLE; ULTRAVIOLET RADIATION; ACTION POTENTIAL; ANIMAL; DRUG EFFECTS; METABOLISM; NEOSTRIATUM; PHOTON; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ACIDS; ACTION POTENTIALS; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; MALE; NEOSTRIATUM; PHENOTHIAZINES; PHOTONS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SUBSTANTIA NIGRA; SYNAPTIC VESICLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84938936856     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1503766112     Document Type: Article

References (30)

1. Strange PG (2008) Antipsychotic drug action: Antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 29(6): 314-321.
2. Dean B, Scarr E (2004) Antipsychotic drugs: Evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord 3(3): 217-225.
3. Rayport S, Sulzer D (1995) Visualization of antipsychotic drug binding to living mesolimbic neurons reveals D2 receptor, acidotropic, and lipophilic components. J Neurochem 65(2): 691-703.
4. Tischbirek CH, et al. (2012) Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron 74(5): 830-844.
5. Morlière P, et al. (2004) An insight into the mechanisms of the phototoxic response induced by cyamemazine in cultured fibroblasts and keratinocytes. Photochem Photobiol 79(2): 163-171.
6. Limones-Herrero D, Pérez-Ruiz R, Jiménez MC, Miranda MA (2014) Retarded photooxidation of cyamemazine in biomimetic microenvironments. Photochem Photobiol 90(5): 1012-1016.
7. Beikmann BS, Tomlinson ID, Rosenthal SJ, Andrews AM (2013) Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells. ACS Chem Neurosci 4(1): 161-170.
8. Karpowicz RJ, Jr, Dunn M, Sulzer D, Sames D (2013) APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter. ACS Chem Neurosci 4(5): 858-869.
9. Chang JC, et al. (2012) Single molecule analysis of serotonin transporter regulation using antagonist-conjugated quantum dots reveals restricted, p38 MAPK-dependent mobilization underlying uptake activation. J Neurosci 32(26): 8919-8929.
10. Sharp T, Zetterström T, Christmanson L, Ungerstedt U (1986) p-Chloroamphetamine releases both serotonin and dopamine into rat brain dialysates in vivo. Neurosci Lett 72(3): 320-324.
11. Rodriguez PC, et al. (2013) Fluorescent dopamine tracer resolves individual dopaminergic synapses and their activity in the brain. Proc Natl Acad Sci USA 110(3): 870-875.
12. Rao A, Richards TL, Simmons D, Zahniser NR, Sorkin A (2012) Epitope-tagged dopamine transporter knock-in mice reveal rapid endocytic trafficking and filopodia targeting of the transporter in dopaminergic axons. FASEB J 26(5): 1921-1933.
13. Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux. Mol Pharmacol 47(3): 544-550.
14. Sulzer D, Rayport S (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action. Neuron 5(6): 797-808.
15. Sulzer D, St Remy C, Rayport S (1996) Reserpine inhibits amphetamine action in ventral midbrain culture. Mol Pharmacol 49(2): 338-342.
16. Partilla JS, et al. (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319(1): 237-246.
17. Sulzer D, et al. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15(5 Pt 2): 4102-4108.
18. Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60(2): 527-535.
19. Sulzer D, et al. (1992) Weak base model of amphetamine action. Ann N Y Acad Sci 654: 525-528.
20. Eiden LE, Schäfer MK, Weihe E, Schütz B (2004) The vesicular amine transporter family (SLC18): Amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 447(5): 636-640.
21. Hyland BI, Reynolds JNJ, Hay J, Perk CG, Miller R (2002) Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience 114(2): 475-492.
22. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75(6): 406-433.
23. Knoth J, Peabody JO, Huettl P, Njus D (1984) Kinetics of tyramine and permeation across cromaffin-vesicle membranes. Biochemistry 23(9): 2011-2016.
24. Romanenko VG, Gebara R, Miller KM, Njus D (1998) Determination of transport parameters of permeant substrates of the vesicular amine transporter. Anal Biochem 257(2): 127-133.
25. Shepard PD, Canavier CC, Levitan ES (2007) Ether-a-go-go-related gene potassium channels: What's all the buzz about? Schizophr Bull 33(6): 1263-1269.
26. Ji H, et al. (2012) Functional characterization of ether-à-go-go-related gene potassium channels in midbrain dopamine neurons-Implications for a role in depolarization block. Eur J Neurosci 36(7): 2906-2916.
27. Tucker KR, Huertas MA, Horn JP, Canavier CC, Levitan ES (2012) Pacemaker rate and depolarization block in nigral dopamine neurons: A somatic sodium channel balancing act. J Neurosci 32(42): 14519-14531.
28. 2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J Neurosci 29(49): 15414-15419.
29. Ungless MA, Grace AA (2012) Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 35(7): 422-430.
30. Rudnick G, Wall SC (1992) p-Chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31(29): 6710-6718.